Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial
详细信息 查看全文
- 作者：Shun Ishibashia ; ishibash@jichi.ac.jp" class="auth_mail" title="E-mail the corresponding author ; Shizuya Yamashitab ; c ; shizu@imed2.med.osaka-u.ac.jp" class="auth_mail" title="E-mail the corresponding author ; Hidenori Araid ; harai@ncgg.go.jp" class="auth_mail" title="E-mail the corresponding author ; Eiichi Arakie ; earaki@gpo.kumamoto-u.ac.jp" class="auth_mail" title="E-mail the corresponding author ; Koutaro Yokotef ; kyokote@faculty.chiba-u.jp" class="auth_mail" title="E-mail the corresponding author ; Hideki Suganamig ; suganami@kowa.co.jp" class="auth_mail" title="E-mail the corresponding author ; Jean-Charles Frucharth ; jean-charles.fruchart@fondacoeur.com" class="auth_mail" title="E-mail the corresponding author ; Tatsuhiko Kodamai ; kodama@lsbm.org" class="auth_mail" title="E-mail the corresponding author ; for the K-877-04 Study Group
- 关键词：SPPARMα ; K-877 ; Pemafibrate ; Triglyceride ; HDL ; Dyslipidaemia
- 刊名：Atherosclerosis
- 出版年：2016
- 出版时间：June 2016
- 年：2016
- 卷：249
- 期：Complete
- 页码：36-43
- 全文大小：698 K
文摘
- class="listitem" id="list_ulist0010">
- class="label">•
About 70% of CVD risk remains even after treatment of high LDL-C by statins.
- class="label">•
To further reduce the residual risk, high TG and low HDL-C are potential targets.
- class="label">•
K-877, a novel SPPARMα, improved high TG and low HDL-C in dyslipidaemic patients.
- class="label">•
K-877 is superior to fenofibrate in terms of efficacy and safety.